*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Trading on Wall Street has gotten off to a volatile start with weak German manufacturing figures sparking worries about global growth, sending traders scurrying for the relative safety of the fixed income space, although some strategists continued to see gains ahead.
Second hand sales of homes in the States rebounded sharply last month, bolstered by lower mortgage rates, growing incomes and improved consumer confidence.
Markets in Asia posted underwhelming gains on Friday, after a choppy session in which investors were still trying to make sense of a more dovish Fed in the US, along with a fresh slew of data.
Biogen shares plummeted on Thursday after the company confirmed that it will cease clinical trials for aducanumab, the experimental Alzheimer’s disease treatment it developed alongside its Nikkei 225-listed Japanese partner Eisai.
European stocks ended Thursday's session mostly lower as investors digested a more dovish than expected policy announcement from the Fed, with banks under pressure.
Perhaps the most widely-followed regional manufacturing gauge in the US rebounded sharply in March, but according to economists continued to point to an ongoing slowdown.
US stocks edged higher in early trade on Thursday as investors mulled fresh readings on manufacturing and jobs and continued to mull over a more dovish than expected policy statement from the Federal Reserve, which has prompted concerns about the US economy.
US jobless claims, one of the most closely-followed indicators of the health of the jobs market, dropped more sharply than expected over the preceding week.
Most markets in Asia were in positive territory as they closed on Thursday, as investors digested news that the US Federal Reserve was standing pat on interest rates, and likely continuing to do so for the rest of the year.
Wall Street's main stockmarket gauges were moving lower on Wednesday as investors opt to stay on the sidelines ahead of the latest policy announcement from the Federal Reserve.
Holland's coalition government is at risk of losing its Senate majority in provincial elections due to be held on Wednesday evening as the Eurosceptic Forum for Democracy climbs in the polls.
Markets in Asia were mostly in negative territory as they closed on Wednesday, as investors struggled to make sense of the latest news from the ongoing trade tensions between the US and China.
International courier services and air freight giant FedEx reported a sharp drop in both sales and profits for its third quarter, blaming its weaker-than-expected performance on its international arm.
US stock futures pointed to a broadly flat open on Wall Street on Wednesday as investors kept their powder dry ahead of the latest policy announcement from the Federal Reserve.
US pharmaceutical group Pfizer has bought a 15% stake in Vivet Therapeutics and now has an exclusive option to buy out the rest of the privately-held French gene therapy company.
